Diabetes - A Growing Opportunity for Investment

Share Article

Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005.

Arrowhead Publishers has announced the release of their new market report: Diabetes – Therapeutics, Diagnostics and Complications (http://www.arrowheadpublishers.com/Diabetes.html).

Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. Overall anti-diabetic drugs sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase and new, oral, injectable and pulmonary premium priced products enter the market to address high unmet clinical needs.

The diabetes therapeutics market is made up of two segments, insulin agents (injectable and pulmonary) and non-insulin agents (oral antidiabetic drugs (OAD) and injectable antidiabetic drugs (IAD)). In 2005 the sale of non-insulin agents accounted for the majority of sales (c.60%, US$10.4 billion) with the remainder derived from insulin products (US$6.9 billion).

Insulin is the gold standard treatment for type 1 diabetes which accounts for 5-10% of diabetic patients. In contrast, non-insulin agents, namely OADs are used as monotherapy or in combination with other OADs or insulin to treat type 2 diabetics.

Growth in the insulin market has outstripped that of the non-insulin market in recent years due to the wider use of insulin in late stage type 2 diabetes and increasing use of insulin analogues versus older cheaper medicines and the uptake of more expensive pens versus the traditional syringes. In addition, the launch of pulmonary insulin’s over the next decade will change the future dynamics of this market. This has been catalysed by the launch of Pfizer’s Exubera in July 2006 and is expected to be closely followed by AERx iDMS (Novo Nordisk/Paradigm), Technosphere inhaled insulin (MannKind) and AIR inhaled insulin (Eli Lilly Alkermes).

Several innovative oral and injectable therapies are in late stage clinical development for the treatment of Type 2 diabetes and will help to expand the repertoire of drugs available to patients. These include the GLP-1 analogues, DPP 4 inhibitors, dual acting PPARs and pan PPARs. These new drugs will continue to fuel the increased appetite for safer and more effective drugs as well as lending themselves to new combination therapies.

Longer term novel approaches to modulating the production and elimination of glucose may prove fruitful targets for pharmaceutical companies and encompass glucose transporter inhibitors and gluconeogenesis inhibitors.

It is estimated that the over US$ 1 billion was spent on the treatment of diabetic neuropathy (DNP) in 2005. This market is expected to grow rapidly over the next five years to generate sales of over US$5.5 billion by 2012. The treatment of diabetic neuropathies is on the verge of revolution as a raft of late stage products begin to emerge including Arxxant (Eli Lilly), Suloxdexide (Keyrx), Ranirestant (Eisai) and TAK 428 (Takeda). However, this has proved a graveyard for drug developers and time will tell if the reward is worth the risk.

The blood glucose monitoring market was estimated to be worth around US$5.0 billion in 2005 and is projected to grow by approximately 15 percent compounded annually. Diabetes diagnostics continue to evolve rapidly as patients migrate to non-invasive monitoring devices from minimally invasive devices. This will aid continuous glucose monitoring and lead to more efficient use of medication.

The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report from Arrowhead Publishers incorporates new clinical findings presented at the 2006 conference of the American Diabetes Association into our product outlooks and financial forecasts. This report breaks down, clinically and financially, the leading products on the market, the major players, as well as the groundbreaking new products in clinical development. Financial forecasts are provided for individual products as well as for classes of products.

1     Summary

2     The Diabetes Market

3     The Facts about Diabetes

4     Patient Statistics

5     Market Drivers

6     Market Resistors

7     Non-Insulin Agents: Attributes, Efficacy & Financial Forecasts

8     Insulin Agents

9     Future Treatments: Non-Insulin

10     Future Treatments: Insulin

11     Alternative Approaches to the Treatment of Diabetes

12     Treatments for Diabetes Complications

13     The Diabetes Diagnostic Market

14     Company Profiles

For more information, visit http://www.arrowheadpublishers.com, or contact us at 1-612-929-5203.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sales Department
Visit website